Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453111 | 0.82 | KMT2A (0.39) | ALDH1A1PKMKMT2AATMSLC1A2 | |
| SCHEMBL2453112 | 0.82 | KMT2A (0.49) | ALDH1A1PKML3MBTL1KMT2AATM | |
| SCHEMBL13441949 | 0.82 | LMNA (0.39) | CA1CA2LMNACA12CA3 | |
| SCHEMBL698898 | 0.79 | ALDH1A1 (0.56) | CA1CA2LMNACA12CA3 | |
| SCHEMBL5161621 | 0.78 | ALDH1A1 (0.42) | CA1CA2LMNAALDH1A1PKM | |
| SCHEMBL1251744 | 0.77 | ALDH1A1 (0.41) | CA1CA2LMNAALDH1A1PKM | |
| SCHEMBL1251745 | 0.77 | ALDH1A1 (0.41) | ALDH1A1PKMKMT2AATMSLC1A2 | |
| SCHEMBL11244303 | 0.77 | LMNA (0.43) | CA1CA2LMNACA12CA3 | |
| SCHEMBL1880935 | 0.76 | LMNA (0.69) | CA1CA2LMNACA12CA3 | |
| SCHEMBL3789746 | 0.76 | LMNA (0.69) | CA1CA2LMNACA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200230253-A1 | CONJUGATE OF IDURONATE-2-SULFATASE | HANMl PHARM. CO., LTD. (KR) | 2020-07-23 | — | — | US | claimed |
| EP-2963055-B1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM IND CO LTD (KR) | 2019-05-15 | — | — | EP | claimed |
| US-20160000931-A1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2016-01-07 | — | — | US | claimed |
| EP-2963055-A1 | SITE-SPECIFIC INSULIN CONJUGATE | Hanmi Pharm. Co., Ltd. (KR) | 2016-01-06 | — | — | EP | claimed |
| US-20230382974-A1 | NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-11-30 | — | — | US | disclosed |
| US-20230330184-A1 | METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230310630-A1 | THERAPEUTIC USE OF COMBINATION COMPRISING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST | HANMI PHARM. CO., LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230302148-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | HANMI PHARM. CO., LTD. (KR) | 2023-09-28 | — | — | US | disclosed |
| US-20230270822-A1 | NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11684655-B2 | Methods of treating neutorpenia using G-CSF protein complex | SPECTRUM PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4197560-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRIPLE-ACTIVATOR PERSISTENT CONJUGATE AS ACTIVE INGREDIENT | Hanmi Pharm. Co., Ltd. (KR) | 2023-06-21 | — | — | EP | disclosed |
| US-20230158117-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| WO-2016168196-A1 | COMPOSITION AND KITS FOR PSEUDOPLASTIC MICROGEL MATRICES | ROCHAL INDUSTRIES, LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160000931-A1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2016-01-07 | — | — | US | disclosed |
| EP-2963055-A1 | SITE-SPECIFIC INSULIN CONJUGATE | Hanmi Pharm. Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| CN-105143255-A | Improved method for preparing physiologically active polypeptide complex with high yield | HANMI PHARM IND CO LTD | 2015-12-09 | — | — | CN | disclosed |
| US-20140065121-A1 | BLOOD PLASMA BASED HYDROGELS FOR TISSUE REGENERATION AND WOUND HEALING APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065106-A1 | Blood Plasma Based Hydrogels for Tissue Regeneration and Wound Healing Applications | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014035721-A1 | BLOOD PLASMA BASED HYDROGELS FOR TISSUE REGENERATION AND WOUND HEALING APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014035725-A1 | BLOOD PLASMA HYDROGELS FOR TISSUE REGENERATION AND WOUND HEALING APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302148-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | GLP1R, GIPR, GCGR | CA1 3332/4885CA2 3898/4885LMNA 3582/4885 |
| US-20230310630-A1 | THERAPEUTIC USE OF COMBINATION COMPRISING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST | ACACA, NR1H4, ACACB | CA1 2043/4885CA2 3056/4885LMNA 4200/4885 |
| US-20230382974-A1 | NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF | GLP1R, GIPR, GCGR | CA1 4227/4885CA2 4058/4885LMNA 4480/4885 |
| US-20230158117-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME | GLP1R, GIPR, GCGR | CA1 2223/4885CA2 4089/4885LMNA 2158/4885 |
| US-20200230253-A1 | CONJUGATE OF IDURONATE-2-SULFATASE | IDUA, FCGR2A, CNDP2 | CA1 677/4885CA2 1052/4885LMNA 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.